Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer. |
| |
| Authors: | K. Matsui N. Masuda M. Fukuoka T. Yana T. Hirashima T. Komiya M. Kobayashi M. Kawahara S. Atagi M. Ogawara S. Negoro S. Kudoh K. Furuse |
| |
| Affiliation: | Second Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Japan. |
| |
| Abstract: | A phase II trial was conducted to evaluate the efficacy and toxicity of the Egorin''s carboplatin dosing formula with 14-day oral etoposide in 38 elderly patients with small-cell lung cancer (SCLC). The overall response rate was 81%. Median survival times were 15.1 months for 16 limited-disease (LD) and 8.6 months for 22 extensive-disease (ED) patients. Myelosuppression was the principal side-effect. This regimen is an active regimen in the treatment of elderly SCLC patients. |
| |
| Keywords: | |
|
